NasdaqGS:MRNABiotechs
Moderna (MRNA) Stock Looks Strong On Returns But Fully Priced On Sales
Moderna stock has delivered a strong 98.6% return over the past year, yet its broader valuation checks still lean expensive, so investors are weighing a sharp share price recovery against signals that the current price may already reflect a lot of optimism.
Moderna is up 98.6% over the last 12 months, which puts recent buyers in a strong position but raises the bar for any further upside to be justified by fundamentals.
Expectations around the company’s vaccine pipeline and cost discipline...